Abstract
BackgroundWe aimed to evaluate the efficacy and safety of phacoemulsification with intravitreal 3 mg triamcinolone acetonide injection in preventing postoperative inflammation and complications in patients with non-infectious anterior uveitis and panuveitis complicated cataract.MethodIn this retrospective cohort study, 140 uveitic cataract patients who received phacoemulsification and intraocular lens implantation in Shanxi Eye hospital from January 2018 to January 2020 were reviewed. The IVTA group (51 eyes of 41 patients) received intravitreal injection of 3 mg triamcinolone acetonide (TA) at the end of surgery, and the control group (51 eyes of 41 patients) without injection matched by propensity score matching were enrolled. Outcome measures were best corrected visual acuity (BCVA), anterior chamber inflammation, intraocular pressure, corneal endothelial cell density, central macular thickness and complications within 3 months follow-up.ResultsThe degree of postoperative anterior chamber inflammation in the IVTA group was lighter than that in the control group (P < 0.05). The postoperative logMAR BCVA of anterior uveitis was better and improved more quickly in the IVTA group(P < 0.05). Postoperative time of using corticosteroids was shorter in the IVTA group as compared to the control group (P < 0.05). The central macular thickness at postoperative month 1 was statistically significantly lower in the IVTA group (P < 0.05). There were no statistically significant differences between the two groups in postoperative corneal endothelial cell density and intraocular pressure (P > 0.05). Two of 51 eyes (3.9%) in the IVTA group and 8 of 51 eyes (15.7%) in the control group had recurrence of uveitis; 6 of 45 eyes (13.3%) in the control group developed cystoid macular edema but none in the IVTA group; 11 of 51 eyes (21.6%) in the IVTA group and 22 of 51 eyes (43.1%) in the control group developed posterior synechiae postoperatively.ConclusionsIntraoperative Intravitreal injection of 3 mg TA is an effective and safe adjunctive therapy for preventing postoperative inflammation and complications to promote early recovery for anterior uveitis or panuveitis complicated cataract patients following phacoemulsification.Trial registrationThis retrospective cohort study was in accordance with the tenets of the Helsinki Declaration and was approved by the Shanxi Eye Hospital Ethics Committee. Written informed consent was obtained from all participants for their clinical records to be used in this study.
Highlights
We aimed to evaluate the efficacy and safety of phacoemulsification with intravitreal 3 mg triamcinolone acetonide injection in preventing postoperative inflammation and complications in patients with non-infectious anterior uveitis and panuveitis complicated cataract
Patient characteristics Overall, a total of 140 patients were reviewed with complete clinical data, including 41 patients who underwent cataract surgery combined with Intravitreal triamcinolone acetonide (IVTA) injection and 99 patients who received cataract surgery alone
After propensity score matching (PSM), 51 eyes of 41 patients were included in the IVTA group and 51 eyes of 41 patients were included in the control group
Summary
We aimed to evaluate the efficacy and safety of phacoemulsification with intravitreal 3 mg triamcinolone acetonide injection in preventing postoperative inflammation and complications in patients with non-infectious anterior uveitis and panuveitis complicated cataract. Uveitis is a leading cause of blindness worldwide, and the development of cataracts is a high-incidence complication due to the intraocular inflammation and/or consequence of long-term treatment with topical, regional and systemic corticosteroids [1,2,3]. The visual outcome of cataract surgery can be unpredictable due to a greater incidence of recurrent inflammation and postoperative complications, such as macular edema, posterior capsule opacification (PCO) and glaucoma [4, 5]. Preoperative and postoperative use of topical and/or systemic corticosteroids is general treatment when patients with non-infectious uveitis receive cataract surgery to restrain the postoperative inflammation. Systemic corticosteroids therapy may accompany significant side effects including gastrointestinal ulcers, osteoporosis, hyperglycaemia, Cushing syndrome, infections and electrolyte disturbance [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
